



The translation of this document is outdated.

Translation validity: 16.10.2017.–09.01.2019.

Amendments not included: 08.01.2019., 15.10.2019.

Text consolidated by Valsts valodas centrs (State Language Centre) with amending regulations of:

- 12 May 2009 [shall come into force from 16 May 2009];
- 3 November 2009 [shall come into force from 28 November 2009];
- 17 May 2011 [shall come into force from 21 May 2011];
- 12 June 2012 [shall come into force from 16 August 2012];
- 11 December 2012 [shall come into force from 23 February 2013];
- 21 May 2013 [shall come into force from 24 May 2013];
- 19 August 2014 [shall come into force from 23 August 2014];
- 26 May 2015 [shall come into force from 1 June 2015];
- 26 April 2016 [shall come into force from 1 May 2016];
- 7 March 2017 [shall come into force from 17 March 2017];
- 10 October 2017 [shall come into force from 16 October 2017].

If a whole or part of a paragraph has been amended, the date of the amending regulation appears in square brackets at the end of the paragraph. If a whole paragraph or sub-paragraph has been deleted, the date of the deletion appears in square brackets beside the deleted paragraph or sub-paragraph.

Republic of Latvia

Cabinet

Regulation No. 847

Adopted 8 November 2005

Regulations Regarding Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia

*Issued pursuant to
Section 3, Paragraph two of the law On Procedures for the Legal Trade
of Narcotic and Psychotropic Substances and Medicinal Products*

1. This Regulation prescribes narcotic substances, psychotropic substances and precursors to be controlled in Latvia.
2. The following shall be controlled in Latvia in accordance with the laws and regulations governing the circulation of narcotic and psychotropic medicinal products and substances:
 - 2.1. prohibited especially dangerous narcotic substances and equivalent psychotropic substances and plants (Schedule I of Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia) (Annex 1);
 - 2.2. very dangerous narcotic substances and equivalent psychotropic substances permitted for medical and scientific use (Schedule II of Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia) (Annex 2);
 - 2.3. dangerous psychotropic substances that can be abused (Schedule III of Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia) (Annex 3);

2.4. derivatives, isomers, structural analogues, active metabolites, esters, ethers, and salts (also salts of isomers, structural analogues, active metabolites, esters, and ethers) of the narcotic substances and psychotropic substances included in Schedule I, II or III of Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia, as well as medicinal products that contain the narcotic and psychotropic substances included in the abovementioned Schedules, unless exceptions are specified in laws and regulations;

2.5. the precursors referred to in Council Regulation (EC) No 111/2005 of 22 December 2004 laying down rules for the monitoring of trade between the Community and third countries in drug precursors and in Annexes to Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004 on drug precursors;

2.6. parts of plants, dried plants, pressed plants, powders, tablets, capsules, extracts, tinctures and any other products of the abovementioned plants that contain the substances included in the Schedule I of Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia, except products that are allowed for distribution in accordance with the laws and regulations regarding food handling.

[12 May 2009; 3 November 2009; 26 May 2015; 7 March 2017]

2.¹ The State Agency of Medicines shall notify regarding changes in Schedules I, II and III of Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia by publishing the information on the website of the State Agency of Medicines (<http://www.zva.gov.lv>).

[17 May 2011]

3. Cabinet Regulation No. 35 of 20 January 2004, Regulations regarding Schedules of Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia (*Latvijas Vēstnesis*, 2004, No. 12), is repealed.

4. Sub-paragraph 7.18 of Annex 1 to this Regulation shall come into force on 1 January 2012.

[17 May 2011]

5. Paragraph 5 of Annex 2 to this Regulation shall come into force on 1 June 2011.

[17 May 2011]

Acting for the Prime Minister, Minister for Justice S. Ābolģina

Minister for Health G. Bērziņš

Annex 1

Cabinet Regulation No. 847
8 November 2005

[11 December 2012; 21 May 2013; 19 August 2014; 26 May 2015; 26 April 2016; 7 March 2017; 10 October 2017]

Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia

Schedule I

(Prohibited especially dangerous narcotic substances, equivalent psychotropic substances and plants, illegal handling and abuse of which endangers health)

1. Substances and plants classified in conformity with the Single Convention on Narcotic Drugs of 30 March 1961:

1.1. synthetic opioid analgesics:

No.	International non-proprietary name (INN)/trivial name	Number in the Chemical Abstracts Service (hereinafter - CAS No.)	Chemical name
1.1.1.	alphacetylmethadol (INN)	1553-31-7	[(3R*,6R*)-6-dimethylamino-4,4-di(phenyl)heptan-3-yl] acetate
1.1.2.	MPPP, desmethyprodine	13147-09-6	(4-phenyl-1-methylpiperidin-4-yl)propanoate

1.1.3.	PEPAP	64-52-8	4-phenyl-1-(2-phenylethyl)piperidin-4-yl acetate
1.1.4.	AH-7921	55154-30-8	3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide
1.1.5.	U-47700	82657-23-6	3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-methylbenzamide
1.1.6.	U-51754	121279-74-1	2-(3,4-dichlorophenyl)-N-[2-(dimethylamino)cyclohexyl]-N-methylacetamide

1.2. morphinan derivatives:

No.	International non-proprietary name (INN)/trivial name	CAS No.	Chemical name
1.2.1.	heroin, morphine diacetate (INN)	561-27-3	(5 α ,6 α)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol diacetate
2.2.1.	desomorphine, <i>Krokodil</i>	427-00-9	4,5- α -epoxy-17-methylmorphinan-3-ol
1.3.2.	etorphine, <i>Immobilon</i> , M99	14521-96-1	(5 α ,7 α)-7-(2-hydroxypentan-2-yl)-6-methoxy-17-methyl-4,5-epoxy-6,14-ethenomorphinan-3-ol
1.2.4.	acetorphine	25333-77-1	4,5 α -epoxy-7 α -(1-hydroxy-1-methylbutyl)-6-methoxy-17-methyl-6,14-endoetheno-morphinan-3-yl acetate

1.3. [10 October 2017]

1.4. products of plant origin with narcotic effect:

No.	Name
1.4.1.	raw opium
1.4.2.	poppy straw
1.4.3.	preparations which are manufactured from any type of poppy if they contain narcotically active opium alkaloids: morphine, codeine, thebaine (extracts, infusions and brews with active substance content in any amount)
1.4.4.	cannabis, cannabis resin, oil, extracts and tinctures
1.4.5.	coca leaf

2. Substances and plants classified in conformity with the Convention on Psychotropic Substances of 21 February 1971:

2.1. phenethylamine derivatives:

No.	International non-proprietary name (INN)/trivial name	CAS No.	Chemical name
2.1.1.	mescaline	54-04-6	2-(3,4,5-trimethoxyphenyl)ethanamine
2.1.2.	fenethylline	3736-08-1	(RS)-1,3-dimethyl-7-[2-(1-phenylpropan-2-ylamino)ethyl]purine-2,6-dione
2.1.3.	fenproporex	16397-28-7	3-(1-phenylpropan-2-ylamino)propanenitrile
2.1.4.	phentermine	122-09-8	2-methyl-1-phenylpropan-2-amine
2.1.5.	mefenorex, Rondimen, Pondinil, Anexate	17243-57-1	3-chloro-N-(1-phenylpropan-2-yl)propan-1-amine
2.1.6.	4-methylaminorex	(\pm)-cis isomers-29493-77-4	4-methyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine
2.1.7.	4,4'-DMAR	1445569-01-6	4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine

2.2. natural substances and derivatives thereof:

No.	International non-proprietary name (INN)/trivial name	CAS No.	Chemical name
2.2.1.	[7 March 2017]		
2.2.2.	7-hydroxymitragynine	174418-82-7	(α E,2S,3S,7aS,12bS)-3-Ethyl-1,2,3,4,6,7,7a,12b-octahydro-7a-hydroxy-8-methoxy- α -

			(methoxymethylene)indolo[2,3-a]quinolizine-2-acetic acid methyl ester
2.2.3.	mitragynine	6202-22-8	(E)-2-[(2S,3S)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[3,2-h]quinolizin-2-yl]-3-methoxyprop-2-enoic acid methyl ester
2.2.4.	salvinorin A	83729-01-5	(2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-2H-benzo[f]isochromene-7-carboxylate
2.2.5.	psilocin, psilocin	520-53-6	3-[2-(dimethylamino)ethyl]-1H-indol-4-ol
2.2.6.	psilocybin	520-52-5	[3-(2-Dimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate

2.3. compounds of other substances:

No.	International non-proprietary name (INN)/trivial name	CAS No.	Chemical name
2.3.1.	tenocyclidine TCP	21500-98-1	1-(1-(2-thienyl)cyclohexyl)piperidine
2.3.2.	eticyclidine PCE	2201-15-2	N-ethyl-1-phenylcyclohexanamine
2.3.3.	rolicyclidine, PHP, PCPY	2201-39-0	1-(1-phenylcyclohexyl)pyrrolidine
2.3.4.	amineptine	57574-09-1	7-[(10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)amino]heptanoic acid
2.3.5.	cathine	492-39-7	(1S,2S)-2-amino-1-phenylpropan-1-ol
2.3.6.	CRA-13	432047-72-8	1-naphthyl[4-(pentyloxy)-1-naphthyl]methanone
2.3.7.	dichloropane	146725-34-0	methyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane-4-carboxylate

2.4. plant products with psychotropic effect:

No.	Name
2.4.1.	<i>catha edulis</i>
2.4.2.	<i>leonotis leonurus</i>
2.4.3.	<i>mitragyna speciosa (kratom)</i>
2.4.4.	<i>nymphaea caerulea</i>
2.4.5.	<i>salvia divinorum</i>
2.4.6.	ephedra plant
2.4.7.	hallucinogenic mushrooms

2.5. psychotropic substances corresponding to the description*:

No.	Name
2.5.1.	2,5-dimethoxyphenyl-ethanamines 2,5-dimethoxyphenyl-ethanamine and any compound derived from 2- (2,5-dimethoxyphenyl)ethanamine: a) by replacing hydrogen atom(s) on the benzene ring with one or several identical or different substitutes or substitutes which form a cyclic structure supplementing the benzene ring; b) by replacing hydrogen atom(s) in an ethylene group with one or several alkyl groups; c) by replacing one or two hydrogen atoms at the nitrogen atom with a not-replaced or replaced alkyl group or by including nitrogen atom in the atom cycle; d) in any of the abovementioned compounds by replacing a hydrogen atom at the nitrogen atom, if it is free, with a not-replaced or replaced hydroxyl group or an acyl group
2.5.2.	3,4-methylenedioxyphenylethanamines 3,4-methylenedioxyphenylethanamine and any compound derived from 2-(3,4-methylenedioxyphenyl)ethanamine: a) by replacing hydrogen atom(s) on the benzene ring with one or several identical or different substitutes or substitutes which form a cyclic structure supplementing the benzene ring; b) by replacing hydrogen atom(s) in an ethylene group with one or several alkyl groups; c) by replacing one or two hydrogen atoms at the nitrogen atom with a not-replaced or replaced alkyl group or by including nitrogen atom in the atom cycle; d) in any of the abovementioned compounds by replacing a hydrogen atom at the nitrogen atom, if it is free, with a not-replaced or replaced hydroxyl group or an acyl group

2.5.3.	<p>Amphetamines 1-phenylpropan-2-amine, its enantiomers and any compound derived from them:</p> <p>a) by not replacing or by replacing one or two hydrogen atoms at the nitrogen atom with not-replaced or replaced alkyl group or including a nitrogen atom in the atom cycle;</p> <p>b) by changing the benzene ring in the compounds referred to in Sub-paragraph "a" with another cyclic structure, different from the benzene ring, which may be replaced;</p> <p>c) by replacing hydrogen atoms on the benzene ring of the compounds referred to in Sub-paragraph "a" with one or several identical or different substitutes or substitutes which form a cyclic structure supplementing the benzene ring;</p> <p>d) by replacing one or several propyl group hydrogen atoms in any of the abovementioned compounds with not-replaced or replaced alkyl group or substitutes which form a benzene ring or a cyclic structure supplementing the cyclic structure referred to in Sub-Paragraph "b";</p> <p>e) in any of the abovementioned compounds by replacing a hydrogen atom at the nitrogen atom, if it is free, with a not-replaced or replaced hydroxyl group or an acyl group</p>
2.5.4.	<p>2-aminoindanes 2-aminoindane or any compound derived from 2-aminoindane:</p> <p>a) by replacing hydrogen atoms on the benzene ring with one or several identical or different substitutes or substitutes which form a cyclic structure supplementing the benzene ring;</p> <p>b) by replacing one or two amino group hydrogen atoms with a not-replaced or replaced alkyl group or by including a nitrogen atom in the atom cycle</p>
2.5.5.	<p>Cyclic derivatives of 2-(2,5-dioxyphenyl)ethanamine Any compound derived from 2-(2,5-dioxyphenyl)ethanamine:</p> <p>a) in the condition 4 of hydrogen atoms by replacing with alkyl group, haloalkane group or halogen atom;</p> <p>b) in addition by replacing hydrogen atom of one hydroxyl group with alkylen group or alkenylen group formed by cycle of 5 or 6 members with the benzene ring in ortho-condition;</p> <p>c) in addition by replacing hydrogen atom of a second hydroxyl group with alkylen group or alkenylen group formed by cycle of 5 or 6 members with the benzene ring in ortho-condition, or methyl group;</p> <p>d) in addition by not replacing or replacing one or two amino group hydrogen atoms or by including in the nitrogen atom cycle;</p> <p>e) in addition by not replacing or replacing one or several ethylene group hydrogen atoms with a not-replaced or replaced alkyl group</p>
2.5.6.	<p>Cathinones 2-amino-1-phenylpropan-1-one and any compound derived from 2-amino-1-phenylpropan-1-one:</p> <p>a) by not replacing or by replacing one or two hydrogen atoms at the nitrogen atom with not-replaced or replaced alkyl or alkoxy group or by including a nitrogen atom in the atom cycle;</p> <p>b) by not replacing or by replacing one or two hydrogen atoms in propanone condition 3 with a not-replaced or replaced alkyl group or alkoxy group or amino group;</p> <p>c) by changing the benzene ring in the compounds referred to in Sub-paragraph "a" or "b" with another cyclic structure, different from the benzene ring, which may be replaced;</p> <p>d) by replacing hydrogen atoms on the benzene ring in any of the compounds referred to in Sub-paragraph "a" or "b" with one or several identical or different substitutes or substitutes which form a cyclic structure supplementing the benzene ring;</p> <p>e) derivatives of any of the abovementioned compound carbonyl group or amino group, or both</p>
2.5.7.	<p>Piperazines Any compound derived from piperazine:</p> <p>a) by replacing a hydrogen atom at one nitrogen atom with a not-replaced or replaced phenyl group, not-replaced or replaced benzyl group or cyclohexyl group;</p> <p>b) by not replacing or by replacing the hydrogen atom at a second nitrogen atom with a not-replaced or replaced methyl group</p>
2.5.8.	<p>Tryptamines and beta-(benzofuran-3-yl)ethanamines Any derivative of beta-(indol-3-yl)ethanamine or beta-(benzofuran-3-yl)ethanamine**** which contains at least one substitute from rows "a", "b" and "c":</p> <p>a) where hydrogen atom(s) on the benzene ring has (have) been replaced with one or several identical or different substitutes or substitutes which form a cyclic structure supplementing the benzene ring;</p> <p>b) where hydrogen atoms in the ethylene group have been replaced with a not-replaced or replaced alkyl group;</p> <p>c) where one or two hydrogen atoms in the amino group have been replaced with a not-replaced or replaced alkyl group, or a nitrogen atom has been included in the cycle</p>
2.5.9.	<p>1-Arylcyclohexylamines and (1-arylcyclohexyl)methanamines 1-arylcyclohexylamines (except ketamine) and (1-arylcyclohexyl)methanamines where the aryl group is a not-replaced or replaced benzene or thiophene cycle, one or two hydrogen atoms in the amino group have been replaced with a not-replaced or replaced alkyl group, or a nitrogen atom has been included</p>

	in the cycle, and the cyclohexane cycle is not replaced or replaced with a carbonyl group, hydroxy group, alkoxy group or alkyl group
2.5.10.	Dibenzopyrans Compounds derived from cannabinol*** modified on the ring A, replaced on the ring B, their homologues with different number of carbon atoms in the substitute in condition 3, cis-, trans- and optical isomers thereof, as well as their derivatives of hydroxyl group and halogen derivatives
2.5.11.	Cyclohexylphenols Any compound derived from 2-(3-hydroxycyclohexyl)phenol: a) by replacing hydrogen atom in condition 5 of phenol cycle; b) in addition by not replacing or by replacing one or several hydrogen atoms in the cyclohexyl group
2.5.12.	Naphthylideneindenes and naphthylmethylindenes Any compound derived from 1-naphthylideneindene or 1-naphthylmethylindene: a) by not replacing or by replacing a hydrogen atom at indene C3 atom; b) in addition by not replacing or by replacing in the compounds referred to in Sub-paragraph "a" one or several hydrogen atoms in the naphthyl group; c) in addition by not replacing or by replacing in the compounds referred to in Sub-paragraph "a" or "b", or both, one or several hydrogen atoms in the indene cycle
2.5.13.	Naphthylmethylindoles Any compound derived from (indol-3-yl)(naphth-1-yl)methane: a) by not replacing or by replacing a hydrogen atom at the indole nitrogen atom; b) in addition by not replacing or by replacing in the compounds referred to in Sub-paragraph "a" one or several hydrogen atoms in the naphthyl group; c) in addition by not replacing or by replacing in the compounds referred to in Sub-paragraph "a" or "b", or both, one or several hydrogen atoms in the indole cycle
2.5.14.	Naphthoylpyrroles Any compound derived from 3-(1-naphthoyl)pyrrole: a) by not replacing or by replacing a hydrogen atom at the pyrrole nitrogen atom; b) in addition by not replacing or by replacing in the compounds referred to in Sub-paragraph "a" one or several hydrogen atoms in pyrrole cycle; c) in addition by not replacing or by replacing in the compounds referred to in Sub-paragraph "a" or "b", or both, one or several hydrogen atoms in the naphthoyl group
2.5.15.	Derivatives of indole, azaindole and indazole-3-carbonyl Derivatives of indole-3-carbonyl, derivatives of azaindol-3-carbonyl, and derivatives of indazole-3-carbonyl which are replaced at indole, azaindol or indazole cycle in condition 1 of the nitrogen atom with a not-replaced or replaced alkyl group and in condition 3 replaced at carbonyl group with: <ul style="list-style-type: none"> • a not-replaced or replaced alkyl group or a cycloalkyl group; • a not-replaced or replaced aromatic or heteroaromatic cycle; • a not-replaced or replaced alkoxy group, aryloxy group, heteroalkoxy group; • a replaced amino group and in the indole or azaindol cycle condition 2 not-replaced or replaced with an alkyl group, and any of the abovementioned compounds which has additionally been replaced in an indole, azaindol or indazole cycle, including such where the substitute makes an additional cycle
2.5.16.	Benzimidazoles Any compound derived from benzimidazole: a) by replacing a hydrogen atom at the nitrogen atom with a not-replaced or replaced alkyl group or a not-replaced or replaced aroyl group; b) in addition by replacing a hydrogen atom at the nitrogen atom of the imidazole cycle with a not-replaced or replaced (hetero)aryl group or a not-replaced or replaced aroyl group; c) in addition by not replacing or replacing hydrogen atoms on the benzene ring of benzimidazole
2.5.17.	Diphenylethanamines 1,2-diphenylethan-1-amine, its enantiomers and any compound derived from them: a) by not replacing or by replacing hydrogen atoms on one or both benzene rings with one or several identical or different substitutes; b) in addition by not replacing or by replacing in the compounds referred to in Sub-paragraph "a" one or both hydrogen atoms of the amino group with a not-replaced or replaced alkyl group or by including it in the cycle; c) in addition by replacing in the compounds referred to in Sub-paragraph "b" one carbon atom on one or both benzene rings with a nitrogen atom
2.5.18.	Derivatives of carbazole-3-carbonyl Derivatives of carbazole-3-carbonyl that have been replaced at the carbazole ring in oxygen atom condition 1 with a not-replaced or replaced alkyl group and condition 3 at carbonyl group is replaced with: a) a not-replaced or replaced alkyl group, cycloalkyl group;

	<p>b) a not-replaced or replaced aromatic or heteroaromatic cycle; c) a not-replaced or replaced alcoxy group, aryloxy group, heteryloxy group; d) a replaced amino group and any of the abovementioned compounds that has been additionally replaced in the carbazole ring</p>
2.5.19.	<p>Derivatives of pyrazole-3-carbonyl Derivatives of pyrazole-3-carbonyl which in condition 3 at carbonyl group are replaced with:</p> <ul style="list-style-type: none"> • a not-replaced or replaced alkyl group or a cycloalkyl group; • a not-replaced or replaced aromatic or heteroaromatic cycle; • a not-replaced or replaced alcoxy group, aryloxy group, heteryloxy group; • a replaced amino group <p>and in pyrazole cycle conditions 1 and 4 (one or both) not replaced or replaced with not-replaced or replaced alkyl groups or aryl groups and in condition 5 replaced with a not-replaced or replaced aryl group</p>
2.5.20.	<p>Derivatives of pyrazole-5-carbonyl Derivatives of pyrazole-5-carbonyl which in condition 5 at carbonyl group are replaced with:</p> <ul style="list-style-type: none"> • a not-replaced or replaced alkyl group or a cycloalkyl group; • a not-replaced or replaced aromatic or heteroaromatic cycle; • a not-replaced or replaced alcoxy group, aryloxy group, heteryloxy group; • a replaced amino group <p>and in pyrazole cycle conditions 1 and 4 (one or both) not replaced or replaced with not-replaced or replaced alkyl groups or aryl groups and in condition 3 replaced with a not-replaced or replaced aryl group</p>
2.5.21.	<p>2-phenylmorpholines 2-phenylmorpholine, its enantiomers and any compound derived from them:</p> <ol style="list-style-type: none"> a) by changing the benzene ring with a thiophene or pyridine ring; b) by changing the morpholine cycle with a thiomorpholine cycle; c) by replacing one or several hydrogen atoms on the benzene, thiophene or pyridine ring with a not-replaced or replaced alkyl group, alcoxy group, amide group, amino group, sulphonyl group or substitutes which form a cyclic structure supplementing the benzene, thiophene or pyridine ring; d) by replacing one or several hydrogen atoms on the benzene, thiophene or pyridine ring with a hydroxyl group or halogen atom; e) by replacing one or several hydrogen atoms on a morpholine or thiomorpholine cycle with a hydroxyl group, nitroso group, carbonyl group or not-replaced or replaced alkyl group
2.5.22.	<p>Lysergamides (or amides of lysergic acid) 4,6,6a,7,8,9-hexahydroindol[4,3-fg]quinoline-9-carboxamide*****, its enantiomers and any compound derived from them:</p> <ol style="list-style-type: none"> a) by not replacing or by replacing one or two hydrogen atoms at the nitrogen atom in an amide group with not-replaced or replaced alkyl group(s) or substitutes that include a nitrogen atom in the atom cycle; b) by not replacing or by replacing the hydrogen atom at the nitrogen atom in a hydrogenated quinoline cycle with a not-replaced or replaced alkyl group; c) by not replacing or by replacing the hydrogen atom at the nitrogen atom in the indole cycle with a not-replaced or replaced alkyl group
2.5.23.	<p>Derivatives of indoline-2-one-3-hydrazine carbonyl Derivatives of indole-2-one-3-hydrazine carbonyl which are replaced at the nitrogen atom in indoline-2-one cycle with a not-replaced or replaced alkyl group and in condition 3 replaced at carbonyl group with:</p> <ul style="list-style-type: none"> • a not-replaced or replaced alkyl group or a cycloalkyl group; • a not-replaced or replaced aromatic or heteroaromatic cycle; • a not-replaced or replaced alcoxy group, aryloxy group, heteryloxy group; • a replaced amino group; <p>and any of the abovementioned compounds in which hydrazine group hydrogen atom is replaced with an alkyl group, or replaced in indoline-2-one cycle</p>
2.5.24.	<p>Gamma-carbonyl-1-ones Any compound derived from 2,5-dihydro-1H-pyrido[4,3-b]indolo-1-one:</p> <ol style="list-style-type: none"> a) by replacing hydrogen atom in condition 5 with a not-replaced or replaced alkyl group or a cycloalkyl group; b) by replacing hydrogen atom in condition 2 with a not-replaced or replaced alkyl group, cycloalkyl group, a not-replaced or replaced aromatic or heteroaromatic cycle, and any of the abovementioned compounds that has been additionally replaced in the carboline cycle
2.5.25.	<p>Acetylfentanyls N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide and any compound derived from N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, if one or several conditions have been met:</p>

- a) by replacing one or several hydrogen atoms on one or both benzene rings with one or several identical or different halogen atoms or alkoxy groups;
- b) by replacing one or several hydrogen atoms in piperidine cycle condition 2, 3, 5, or 6 with a not-replaced or replaced alkyl group;
- c) by replacing one or several ethylene group hydrogen atoms with a not-replaced or replaced alkyl group or hydroxyl group;
- d) by replacing one or several hydrogen atoms in acetyl group with a not-replaced or replaced alkyl group(s), alkenyl group, methoxy group or by including a carbon atom in a cycle which may be replaced, including by creating supplementing cycles;
- e) by replacing ethylene group with a methylene group;
- f) by replacing hydrogen atom in condition 5 of piperidine cycle with a replaced or not-replaced phenyl group or ester group;
- g) by changing the benzene ring present in N-(1-phenethylpiperidin-4-yl) group with another cyclic structure, different from the benzene ring, which may be replaced;
- h) by changing the benzene ring of N-phenyl group with another saturated structure, different from the benzene ring, which may be replaced

Notes.

1. * If the substance is also referred to in Annex 2 or 3 to this Regulation, it shall not be applicable to Annex 1.
2. ** Except ketamine.
3. *** Except cannabidiol.
4. **** Except serotonin, sumatriptan, zolmitriptan.
5. ***** Except ergometrine, ergotamine, methylethergometrine, methysergide.

Annex 2
Cabinet Regulation No. 847
8 November 2005

[10 October 2017]

Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia

Schedule II

(Very dangerous narcotic substances and equivalent psychotropic substances permitted for medical and scientific use)

1. Substances classified in conformity with Schedule I of the Single Convention on Narcotic Drugs of 30 March 1961:

No.	International non-proprietary name (INN)/trivial name	CAS No.
1.1.	acetylmethadol	509-74-0
1.2.	alfentanil	71195-58-9
1.3.	allylprodine	25384-17-2
1.4.	alphameprodine	468-51-9
1.5.	alphamethadol	17199-54-1
1.6.	alphaprodine	77-20-3
1.7.	anileridine	144-14-9
1.8.	benzethidine	3691-78-9
1.9.	benzylmorphine	14297-87-1
1.10.	betacetylmethadol	17199-59-6
1.11.	betameprodine	468-50-8
1.12.	betamethadol	17199-55-2
1.13.	betaprodine	468-59-7

1.14.	bezitramide	15301-48-1
1.15.	dextromoramide	357-56-2
1.16.	diampromide	552-25-0
1.17.	diethylthiambutene	86-14-6
1.18.	difenoxin	28782-42-5
1.19.	dihydroetorphine	14357-76-7
1.20.	dihydromorphine	509-60-4
1.21.	dimenoxadol	509-78-4
1.22.	dimepheptanol	545-90-4
1.23.	dimethylthiambutene	524-84-5
1.24.	dioxaphetyl butyrate	467-86-7
1.25.	diphenoxylate	915-30-0
1.26.	dipipanone	467-83-4
1.27.	drotebanol	3176-03-2
1.28.	ecgonine, esters thereof and derivatives which may be converted into ecognine and cocaine	481-37-8
1.29.	ethylmethylthiambutene	441-61-2
1.30.	etoxeridine	469-82-9
1.31.	etonitazene	911-65-9
1.32.	phenadoxone	467-84-5
1.33.	phenampromide	129-83-9
1.34.	phenazocine	127-35-5
1.35.	phenomorphan	468-07-5
1.36.	phenoperidine	562-26-5
1.37.	fentanyl	437-38-7
1.38.	furethidine	2385-81-1
1.39.	hydrocodone	125-29-1
1.40.	hydromorhinol	2183-56-4
1.41.	hydromorphone	466-99-9
1.42.	hydroxypethidine	468-56-4
1.43.	isomethadone	466-40-0
1.44.	ketobemidone	469-79-4
1.45.	clonitazene	3861-76-5
1.46.	codoxime	7125-76-0
1.47.	cocaine	50-36-2
1.48.	levophenacymorphan	10061-32-2
1.49.	levomethorphan	125-70-2
1.50.	levomoramide	5666-11-5
1.51.	levorphanol	77-07-6
1.52.	methadone	76-99-3
1.53.	methadone intermediate	125-79-1
1.54.	metazocine	3734-52-9
1.55.	methyl-desorphine	16008-36-9
1.56.	methyldihydromorphine	509-56-8
1.57.	metopon	143-52-2
1.58.	moramide intermediate	3626-55-9
1.59.	morpheridine	469-81-8
1.60.	morphine	57-27-2
1.61.	morphine methobromide and other morphine derivatives containing pentavalent nitrogen	125-23-5
1.62.	morphine-N-oxide	639-46-3
1.63.	myrophine	467-18-5
1.64.	nicomorphine	639-48-5

1.65.	noracymethadol	1477-39-0
1.66.	norlevorphanol	1531-12-0
1.67.	normethadone	467-85-6
1.68.	normorphine	466-97-7
1.69.	norpipanone	561-48-8
1.70.	oxycodone	76-42-6
1.71.	oxymorphone	76-41-5
1.72.	opium	not specified
1.73.	pethidine	57-42-1
1.74.	pethidine intermediate A	3627-62-1
1.75.	pethidine intermediate B	77-17-8
1.76.	pethidine intermediate C	3627-48-3
1.77.	piminodine	13495-09-5
1.78.	piritramide	302-41-0
1.79.	proheptazine	77-14-5
1.80.	properidine	561-76-2
1.81.	racemethorphan	510-53-2
1.82.	racemoramide	545-59-5
1.83.	racemorphan	297-90-5
1.84.	remifentanil	132875-61-7
1.85.	sufentanil	56030-54-7
1.86.	thebacon	466-90-0
1.87.	thebaine	115-37-7
1.88.	tilidine	20380-58-9
1.89.	trimeperidine	64-39-1

2. Substances classified in conformity with Schedule II of the Single Convention on Narcotic Drugs of 30 March 1961:

No.	International non-proprietary name (INN)/trivial name	CAS No.
2.1.	acetyldihydrocodeine	3861-72-1
2.2.	dextropropoxyphene	469-62-5
2.3.	dihydrocodeine	125-28-0
2.4.	ethylmorphine	76-58-4
2.5.	pholcodine	509-67-1
2.6.	codeine	76-57-3
2.7.	nicocodine	3688-66-2
2.8.	nicodicodine	808-24-2
2.9.	norcodeine	467-15-2
2.10.	propiram	15686-91-6

3. Substances classified in conformity with Schedule II of the Convention on Psychotropic Substances of 21 February 1971:

No.	International non-proprietary name (INN)/trivial name	CAS No.
3.1.	zipeprol	34758-83-3
3.2.	dronabinol (delta-9-tetrahydrocannabinol and its stereochemical variants)	1972- 08-3 (CAS No. indicated for substance "dronabinol")
3.3.	phencyclidine (PCP)	77-10-1
3.4.	phenmetrazine	134-49-6
3.5.	mecloqualone	340-57-8
3.6.	methaqualone	72-44-6
3.7.	methylphenidate	113-45-1
3.8.	secobarbital	76-73-3

3.9.	gamma-hydroxybutyric acid (GHB)	591-81-1
3.10.	methyldormphenate	231299-92-6

4. Substances classified in conformity with Schedule III of the Convention on Psychotropic Substances of 21 February 1971:

No.	International non-proprietary name (INN)/trivial name	CAS No.
4.1.	amobarbital	57-43-2
4.2.	buprenorphine	52485-79-7
4.3.	butalbital	77-26-9
4.4.	cyclobarbital	52-31-3
4.5.	flunitrazepam	1622-62-4
4.6.	glutethimide	77-21-4
4.7.	hexobarbital	56-29-1
4.8.	pentazocine	359-83-1
4.9.	pentobarbital	76-74-4

5. Narcotic substance, illicit circulation and abuse of which may endanger health

No.	International non-proprietary name (INN)/trivial name	CAS No.
5.1.	tapentadol	175591-09-0

Annex 3

Cabinet Regulation No. 847
8 November 2005

[10 October 2017]

Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia

Schedule III

(Dangerous psychotropic substances that can be abused)

Substances classified in conformity with Schedule IV of the Convention on Psychotropic Substances of 21 February 1971:

No.	International non-proprietary name (INN)/trivial name	CAS No.
1.	Allobarbital	52-43-7
2.	Alprazolam	28981-97-7
3.	Amfepramone	90-84-6
4.	Aminorex	2207-50-3
5.	Barbital	57-44-3
6.	Benzfetamine	156-08-1
7.	Bromazepam	1812-30-2
8.	Brotizolam	57801-81-7
9.	Butobarbital	77-28-1
10.	Cephedrine	67055-59-8
11.	Delorazepam	2894-67-9
12.	Diazepam	439-14-5
13.	Ephedrine*	299-42-3
14.	Estazolam	29975-16-4
15.	Ethchlorvynol	113-18-8
16.	Ethinamate	126-52-3

17.	Ethyl loflazepate	29177-84-2
18.	Phenatine	139-68-4
19.	Fenazepam	51753-57-2
20.	Fencamfamin	1209-98-9
21.	Phendimetrazine	634-03-7
22.	Phenobarbital	50-06-6
23.	Fludiazepam	3900-31-0
24.	Flurazepam	17617-23-1
25.	Halazepam	23092-17-3
26.	Haloxazolam	59128-97-1
27.	Chlordiazepoxide	58-25-3
28.	Camazepam	36104-80-0
29.	Ketazolam	27223-35-4
30.	Clobazam	22316-47-8
31.	Cloxazolam	24166-13-0
32.	Clonazepam	1622-61-3
33.	Clorazepate	23887-31-2
34.	Clotiazepam	33671-46-4
35.	Lefetamine (SPA)	7262-75-1
36.	Loprazolam	61197-73-7
37.	Lorazepam	846-49-1
38.	Lormetazepam	848-75-9
39.	Mazindol	22232-71-9
40.	Medazepam	2898-12-6
41.	Meprobamate	57-53-4
42.	Methylphenobarbital	115-38-8
43.	Methyprylon	125-64-4
44.	Mesocarb	34262-84-5
45.	Midazolam	59467-70-8
46.	Nimetazepam	2011-67-8
47.	Nitrazepam	146-22-5
48.	Nordazepam	1088-11-5
49.	Oxazepam	604-75-1
50.	Oxazolam	24143-17-7
51.	Pemoline	2152-34-3
52.	Pinazepam	52463-83-9
53.	Pipradrol	467-60-7
54.	Pyrovalerone	3563-49-3
55.	Prazepam	2955-38-6
56.	Propanidid	1421-14-3
57.	Pseudoephedrine*	90-82-4
58.	Secbutabarbital	125-40-6
59.	Temazepam	846-50-4
60.	Tetrazepam	10379-14-3
61.	Tofisopam	22345-47-7
62.	Triazolam	28911-01-5
63.	Trihexyphenidyl	144-11-6
64.	Vinylbital	2430-49-1
65.	Zolpidem	82626-48-0
66.	Zopiclone	43200-80-2
67.	Tramadol	27203-92-5
68.	Derivative of alprazolam triazolo-benzophenone	Not available

69.	Deschloroetizolam	40054-73-7
70.	Metizolam	40054-68-0
71.	Nitrazolam	28910-99-8
72.	Pyrazolam	39243-02-2

Note. * The procedures specified by regulatory enactments in the field of pharmacy shall also be observed during control.

Translation © 2018 Valsts valodas centrs (State Language Centre)

© Oficiālais izdevējs "Latvijas Vēstnesis"